苏州大学附属第一医院
First Affiliated Hospital of Soochow University
在本站收录的 53 种疾病中,这家医院列在其中 29 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
苏州大学附属第一医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma8 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma22 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma73 篇牵头论文
- 胃癌Stomach cancer90 篇牵头论文牵头 2 项开放试验
- 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
- 脊索瘤Chordoma2 篇牵头论文
- 骨肉瘤Osteosarcoma4 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour6 篇牵头论文
- 神经母细胞瘤Neuroblastoma1 篇牵头论文
- 多发性骨髓瘤Multiple myeloma27 篇牵头论文牵头 7 项开放试验
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia12 篇牵头论文牵头 10 项开放试验
- 再生障碍性贫血Aplastic anaemia11 篇牵头论文牵头 2 项开放试验
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis6 篇牵头论文牵头 2 项开放试验
- β 地中海贫血Beta thalassaemia1 篇牵头论文
- 血友病 AHaemophilia A6 篇牵头论文
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura5 篇牵头论文牵头 1 项开放试验
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder10 篇牵头论文
- 重症肌无力Myasthenia gravis9 篇牵头论文
- 烟雾病Moyamoya disease3 篇牵头论文
- 肝豆状核变性Wilson disease2 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
- 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文
- 法布雷病Fabry disease3 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy2 篇牵头论文
- 白塞病Behçet disease0 篇牵头论文
- IgA 肾病IgA nephropathy2 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
未列出的收录疾病:肝母细胞瘤、尤文肉瘤、非典型溶血性尿毒症综合征、范可尼贫血、IgG4相关性疾病、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 2 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文8
- Expression and functional implications of YME1L in nasopharyngeal carcinoma.
- Prognostic modeling for nasopharyngeal carcinoma (NC) undergoing concurrent chemoradiotherapy using clinical and enhanced MRI-Delta radiomics data: A preliminary study.
- Syncope as the initial symptom in a patient with nasopharyngeal carcinoma: a case report.
- Overexpressed Gαi1 exerts pro-tumorigenic activity in nasopharyngeal carcinoma.
- CircKIAA0368 Promotes Proliferation, Migration, and Invasion by Upregulating HOXA10 in Nasopharyngeal Carcinoma.
- Let-7i-5p promotes a malignant phenotype in nasopharyngeal carcinoma via inhibiting tumor-suppressive autophagy.
- Key genes affecting the progression of nasopharyngeal carcinoma identified by RNA-sequencing and bioinformatic analysis.
- Continuous quality improvement of nutrition management during radiotherapy in patients with nasopharyngeal carcinoma.
PubMed 以外找到的论文(未计入)13
- Salivary metabolomic profiling reveals dynamic metabolic adaptations in nasopharyngeal carcinoma (NPC) patients during radiotherapy
- Prediction of Parotid Gland Changes in Radiation-Induced Oral Mucositis of Nasopharyngeal Carcinoma Based on Metabolism-Imaging Bimodal Omics
- Additional file 1 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 2 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 3 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 4 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 5 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 6 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 7 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Advances of radiotherapy combined with targeted therapy for nasopharyngeal carcinoma
- Efficacy and safety of penpulimab-containing regimens for advanced malignant solid tumors that have failed immunotherapy: A real-world study.
- Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma
- Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 22 篇,占 0.8%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 3 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
牵头的论文22
- RRP9 Promotes Esophageal Squamous Cell Carcinoma Progression through E2F1 Transcriptional Regulation of CDK1.
- Organoid-based two-step drug screening for rapid identification of chemotherapy-resistant oesophageal squamous cell carcinoma and alternative therapies.
- Correlation of immune cell subsets in the tumor microenvironment and peripheral blood with immunotherapy response in esophageal squamous cell carcinoma.
- Decursin Suppresses Esophageal Squamous Cell Carcinoma Progression via Orchestrated Cell Cycle Deceleration, Apoptotic Activation, and Oncoprotein Degradation.
- A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy with or witho
- Improved circulating tumor DNA identification for detection of esophageal squamous cell carcinoma by enzymatic methyl sequencing and hybrid neural network.
- Explainable semi-supervised model for predicting invasion depth of esophageal squamous cell carcinoma based on the IPCL and AVA patterns.
- Diagnostic Efficacy of Type B Vessels in the Japan Esophageal Society Classification for the Depth of Invasion of Superficial Esophageal Squamous Cell Carcinoma.
- Integrating 18F-FDG PET/CT radiomics and body composition for enhanced prognostic assessment in patients with esophageal cancer.
- First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial.
- Spatial transcriptome profiling identifies DTX3L and BST2 as key biomarkers in esophageal squamous cell carcinoma tumorigenesis.
- A prognostic nomogram for T3N0M0 esophageal squamous cell carcinoma patients undergoing radical surgery based on computed tomography radiomics and inflammatory nutritional biomarkers.
- RGS16 regulates Hippo-YAP activity to promote esophageal cancer cell proliferation and migration.
- Multi-omics analyses reveal spatial heterogeneity in primary and metastatic oesophageal squamous cell carcinoma.
- Peripheral Blood Markers Predictive of Progression-Free Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With PD-1 Inhibitors Plus Chemotherapy as First-Line Therapy.
- Sesamin exerts anti-tumor activity in esophageal squamous cell carcinoma via inhibition of TRIM44 and NF-κB signaling.
- Verbascoside represses malignant phenotypes of esophageal squamous cell carcinoma cells by inhibiting CDC42 via the HMGB1/RAGE axis.
- microRNA-497-mediated Smurf2/YY1/HIF2α axis in tumor growth and metastasis of esophageal squamous cell carcinoma.
- Esophageal carcinosarcoma comprising undifferentiated pleomorphic sarcoma and squamous cell carcinoma: a case report.
- Overcoming radio-resistance in esophageal squamous cell carcinoma via hypermethylation of PIK3C3 promoter region mediated by KDM5B loss.
- Can Lymphovascular Invasion be Predicted by Preoperative Contrast-Enhanced CT in Esophageal Squamous Cell Carcinoma?
- Mechanism and Role of the Neuropeptide LGI1 Receptor ADAM23 in Regulating Biomarkers of Ferroptosis and Progression of Esophageal Cancer.
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora
- Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma
- Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
PubMed 以外找到的论文(未计入)18
- A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy with or witho
- Abstract 1945: High-sensitive gastrointestinal cancers early detection by cell-free DNA targeted methylation sequencing with an innovative modeling approach
- Additional file 1 of A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradio
- ESCC-eCura: A Novel Scoring System to Assess Curability after Endoscopic Submucosal Dissection for Superficial Esophageal Squamous Cell Carcinoma
- Kurarinone's synergistic target space and therapeutic promise for esophageal squamous cell carcinoma are revealed by systems pharmacology
- Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial
- Regulation and function of the RSK family in colorectal cancer
- Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
- Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma
- Exosomal miR-29b-3p derived from cancer- associated fibroblasts contributes to esophageal squamous cell carcinoma cell progression by NAA60 hypomethylation
- Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial
- LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling
- The preliminary efficacy and safety of KN046 plus concurrent chemoradiation therapy in recurrent and metastatic esophageal squamous cell carcinoma.
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 73 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 2 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。
这些数字背后的记录
牵头的论文73
- Gd-EOB-DTPA-enhanced MRI radiomics and deep learning models for predicting the pathological differentiation degree in hepatocellular carcinoma.
- Functional regulatory roles of HNF1B in promoting cell proliferation, migration, invasion and fate decision of hepatocellular carcinoma.
- Hepatocellular carcinoma (HCC) and focal nodular hyperplasia (FNH) showing iso- or hyperintensity in the hepatobiliary phase: differentiation using Gd-EOB-DTPA enhanced MRI radiomics and deep learning features.
- A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma.
- Construction of an Oxidative Stress Risk Model to Analyze the Correlation Between Liver Cancer and Tumor Immunity.
- Clinical characteristics and risk factors of hepatocellular carcinoma development in Budd-Chiari syndrome patients after endovascular treatment.
- FBXO42 promotes hepatocellular carcinoma progression via mediating p57Kip2 ubiquitination and degradation.
- CircBRWD1 promotes hepatitis B virus replication and hepatocellular carcinoma progression by regulating the miR-513a-5p/TNPO1 axis.
- Survival benefits of different immunotherapies for hepatocellular carcinoma: a meta-analysis highlighting age, gender, etiology, and tumor burden.
- KRT80 in hepatocellular carcinoma plays oncogenic role via epithelial-mesenchymal transition and PI3K/AKT pathway.
- Prexasertib exerts a synergistic effect on the antitumor activity of Lenvatinib through ALOX15-mediated ferroptosis in hepatocellular carcinoma.
- Safety and efficacy of TACE combined with immune checkpoint inhibitors plus molecular targeted therapies in older adults with unresectable hepatocellular carcinoma.
- Transarterial chemoembolization combined with percutaneous ethanol injection for the treatment of hepatocellular carcinoma at high-risk areas.
- Heterogeneity Habitats -Derived Radiomics of Gd-EOB-DTPA Enhanced MRI for Predicting Proliferation of Hepatocellular Carcinoma.
- Deep Learning Radiopathomics Models Based on Contrast-enhanced MRI and Pathologic Imaging for Predicting Vessels Encapsulating Tumor Clusters and Prognosis in Hepatocellular Carcinoma.
- PARK7-driven IGF2BP3-K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma.
- Development and validation of a prealbumin-bilirubin model for prognostic prediction in intermediate hepatocellular carcinoma undergoing transarterial chemoembolization.
- Efficacy and safety of hepatic arterial infusion chemotherapy followed by transarterial embolization for hepatocellular carcinoma.
- Emergent TIPS for acute gastroesophageal variceal bleeding in cirrhotic patients with hepatocellular carcinoma.
- Tim-1-mediated extracellular matrix promotes the development of hepatocellular carcinoma.
- Identification and evaluation of plasma exosome RNA biomarkers for non-invasive diagnosis of hepatocellular carcinoma using RNA-seq.
- Gd-EOB-DTPA enhanced MRI nomogram model to differentiate hepatocellular carcinoma and focal nodular hyperplasia both showing iso- or hyperintensity in the hepatobiliary phase.
- miR-29a-SIRT1-Wnt/β-Catenin Axis Regulates Tumor Progression and Survival in Hepatocellular Carcinoma.
- Long Non-coding RNA LINC00342 Promotes the Proliferation, Invasion, and Migration of Primary Hepatocellular Carcinoma Cells by Regulating the Expression of miRNA-19a-3p, miRNA-545-5p, and miRNA-203a-3p.
- Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8+T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model.
- The Incidences and Related CT Features of Vascular Lake Phenomenon on Angiography Before Chemoembolization.
- Transarterial chemoembolization refractoriness in hepatocellular carcinoma: Chinese College of Interventionalists definition and consensus statement.
- Radiomic Analysis of Contrast-Enhanced CT Predicts Glypican 3-Positive Hepatocellular Carcinoma.
- Cryoablation combined with dual immune checkpoint blockade enhances antitumor efficacy in hepatocellular carcinoma model mice.
- Which risk model can better predict hepatocellular carcinoma in hepatitis B patients with an antiviral treatment duration of over 1 year?
- Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α.
- Machine learning based on gadoxetic acid-enhanced MRI for differentiating atypical intrahepatic mass-forming cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.
- Circular RNA hsa_circ_0005239 contributes to hepatocellular carcinoma cell migration, invasion, and angiogenesis by targeting the miR-34a-5p/PD-L1 axis.
- Cuproptosis-related lncRNAs predict the prognosis and immune response in hepatocellular carcinoma.
- The Role of Oxidative Stress in the Development and Therapeutic Intervention of Hepatocellular Carcinoma.
- Letter re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
- Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.
- LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathway.
- Nomogram Estimating Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma From Preoperative Gadoxetate Disodium-Enhanced MRI.
- Preoperative Diagnosis of Dual-Phenotype Hepatocellular Carcinoma Using Enhanced MRI Radiomics Models.
- LINC00106/RPS19BP1/p53 axis promotes the proliferation and migration of human prostate cancer cells.
- Global profiling of protein lysine lactylation and potential target modified protein analysis in hepatocellular carcinoma.
- Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma.
- hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miR-139-3p/CCL5 axis.
- Preoperative CECT-based Radiomic Signature for Predicting the Response of Transarterial Chemoembolization (TACE) Therapy in Hepatocellular Carcinoma.
- LINC02535/miR-30a-5p/GALNT3 axis contributes to lung adenocarcinoma progression via the NF- κ B signaling pathway.
- Gd-EOB-DTPA-enhanced MRI radiomics to predict vessels encapsulating tumor clusters (VETC) and patient prognosis in hepatocellular carcinoma.
- Hypothyroidism has a protective causal association with hepatocellular carcinoma: A two-sample Mendelian randomization study.
- Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.
- Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response.
- Comprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma.
- Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty live
- Re: "Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis".
- Insights into the Allosteric Effect of SENP1 Q597A Mutation on the Hydrolytic Reaction of SUMO1 via an Integrated Computational Study.
- Cytotoxic and anti-tumor effects of 3,4-seco-lupane triterpenoids from the leaves of Eleutherococcus sessiliflorus against hepatocellular carcinoma.
- Immune suppressive function of IL-1α release in the tumor microenvironment regulated by calpain 1.
- Activating transcription factor 2 promotes the progression of hepatocellular carcinoma by inducing the activation of the WHSC1-mediated TOP2A/PI3K/AKT axis.
- Lysine demethylase 5C epigenetically reduces transcription of ITIH1 that results in augmented progression of liver hepatocellular carcinoma.
- Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
- LncRNA PCGEM1 mediates oxaliplatin resistance in hepatocellular carcinoma via miR-129-5p/ETV1 axis in vitro.
- RUFY3 promotes the progression of hepatocellular carcinoma through activating NF-κB-mediated epithelial-mesenchymal transition.
- Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma.
- MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling.
- Integrated I-125 Seed Implantation Combined with Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombus.
- Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
- CT-based radiomics model to distinguish necrotic hepatocellular carcinoma from pyogenic liver abscess.
- Silencing PFKP restrains the stemness of hepatocellular carcinoma cells.
- Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
- ceRNA network development and tumor-infiltrating immune cell analysis in hepatocellular carcinoma.
- miR-760 mediated the proliferation and metastasis of hepatocellular carcinoma cells by regulating HMGA2.
- cFUT8 promotes liver cancer progression by miR-548c/FUT8 axis.
- Imaging features based on Gd-EOB-DTPA-enhanced MRI for predicting vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma.
- Correlation of radiomic features on dynamic contrast-enhanced magnetic resonance with microvessel density in hepatocellular carcinoma based on different models.
中文论文(未计入)7
- [Diagnosis and differential diagnosis of small hepatocellular carcinoma in the context of cirrhosis].
- [Efficacy and safety of transarterial chemoembolization combined with sintilimab and bevacizumab biosimilar for unresectable hepatocellular carcinoma].
- [Diagnostic value of Gd-EOB-DTPA-enhanced MRI radiomics models for dual-phenotype hepatocellular carcinoma].
- [Construction of a prognostic model for hepatocellular carcinoma based on pyroptosis-related genes].
- [The application value of Gd-EOB-DTPA enhanced MRI based radiomics in the differential diagnosis of iso-or hyperintensity HCC and focal nodular hyperplasia in hepatobiliary phase].
- [The prediction value of enhanced magnetic resonance imaging nomogram model for dual phenotype hepatocellular carcinoma].
- [Value of the application of enhanced CT radiomics and machine learning in preoperative prediction of microvascular invasion in hepatocellular carcinoma].
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
- Evaluate the Effect of Tirazamine on Primary Liver Cancer.
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
- The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
- Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 90 篇,占 0.9%。
苏州有 3 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging
- 分期
- 未注明
- 开始
- 2026-05
- 登记号
- NCT07551466
年龄 18 岁 至 80 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
- 分期
- II期
- 开始
- 2025-04
- 登记号
- NCT07012447
年龄 14 岁 至 未注明(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- 分期
- III期
- 开始
- 2026-04
- 登记号
- NCT07385703
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- 分期
- 未注明
- 开始
- 2023-09
- 登记号
- NCT06035250
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛
- 即将招募Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
- 分期
- 未注明
- 开始
- 2026-10
- 登记号
- NCT07902596
年龄 18 岁 至 未注明(登记的条件)
牵头:江苏省人民医院(南医大一附院);另有 6 家列出的医院为研究中心上海、南京、石家庄、苏州、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文90
- Integrating narrative therapy and sleep intervention to enhance recovery, nutritional reconstitution, and 24-month survival following curative gastrectomy: a randomized controlled trial.
- Psychosocial intervention to improve sleep, psychological adjustment, and quality of life in gastric cancer patients undergoing gastrectomy: a randomized controlled trial.
- Combined Effects of Psychological Intervention and Enhanced Nutritional Support on Postoperative Recovery in Gastric Cancer Patients.
- Combined sleep intervention and nutritional support to enhance postoperative recovery in gastric cancer: a prospective randomized controlled trial.
- Targeting PTBP3-Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis.
- Virtual NBI image synthesis using stable diffusion for enhanced recognition of early gastric cancer: a technical validation study.
- Artificial intelligence-assisted diagnosis of early gastric cancer: present practice and future prospects.
- Psychological Interventions and Sleep Improvement for Patients with Gastric Cancer: Effects on Immune Function, Inflammation, and Tumor Progression-A Randomized Controlled Trial.
- The LINC01094/miR-545-3p/SLC7A11 Signaling Axis Promotes the Development of Gastric Cancer by Regulating Cell Growth and Ferroptosis.
- Artificial intelligence-driven microRNA signature for early detection of gastric cancer: discovery and clinical functional exploration.
- JMJD3 upregulates ALOX5 to drive malignancy and concomitant ferroptosis sensitivity in gastric cancer.
- Tumor exosomal circPTBP3 drives gastric cancer peritoneal metastasis via mesothelial-mesenchymal transition.
- CST1 promoted gastric cancer development by activating the AKT pathway.
- Enhancing short-term recovery after gastric cancer surgery: an information-motivation-behavioral skills (IMB) model with nutritional support.
- HIF-1α Promotes the Confined Migration of Gastric Cancer Cells by Modulating Phosphatidylcholine Metabolism.
- N‑methyladenosine reader YTHDF2‑mediated AC026691.1 degradation promotes gastric cancer cell proliferation, migration and M2 macrophage polarization.
- CBX4 Drives Gastric Cancer Progression by Activating β-Catenin Signaling.
- FBLN2 inhibits gastric cancer proliferation and metastasis via the TGFβ/TGIF2 pathway.
- Coprevalence of modifiable gastric cancer risk factors and gastric health among Chinese high-risk groups.
- Identification of a LncRNA based CeRNA network signature to establish a prognostic model and explore potential therapeutic targets in gastric cancer.
- B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy.
- Predicting esophagojejunal anastomotic leakage in gastric cancer patients after total gastrectomy: Development and assessment of a new predictive nomogram.
- Glycolysis-related genes predict prognosis and indicate immune microenvironment features in gastric cancer.
- Differentially expressed microRNA in prognosis of gastric cancer with Lauren classification.
- Exosome-derived proteins in gastric cancer progression, drug resistance, and immune response.
- TREM1 facilitates the development of gastric cancer through regulating neutrophil extracellular traps-mediated macrophage polarization.
- From mitochondria to tumor suppression: ACAT1's crucial role in gastric cancer.
- ITGBL1 promotes anoikis resistance and metastasis in human gastric cancer via the AKT/FBLN2 axis.
- FOLR2+ macrophage depletion from intestinal metaplasia to early gastric cancer: single-cell sequencing insight into gastric cancer progression.
- BUB1 potentiates gastric cancer proliferation and metastasis by activating TRAF6/NF-κB/FGF18 through m6A modification.
- Construction of a TAN-associated risk score model with integrated multi-omics data analysis and clinical validation in gastric cancer.
- Cancer-associated fibroblasts promote proliferation, angiogenesis, metastasis and immunosuppression in gastric cancer.
- ARTN-GFRA3 axis induces epithelial-mesenchymal transition phenotypes, migration, and invasion of gastric cancer cells via KRAS signaling.
- Comparison analysis of two different types of endoscopic resection procedures in small gastric subepithelial tumours originating frommuscularis propria.
- PRSS2 regulates EMT and metastasis via MMP-9 in gastric cancer.
- Identification and validation of crucial lnc-TRIM28-14 and hub genes promoting gastric cancer peritoneal metastasis.
- The combination of preoperative fibrinogen-to-albumin ratio and postoperative TNM stage (FAR-TNM) predicts the survival in gastric cancer patients after gastrectomy.
- Feasibility evaluation of hsa_circ_0005480 as an auxiliary diagnostic and prognostic indicator for gastric cancer.
- Loss of NDUFS1 promotes gastric cancer progression by activating the mitochondrial ROS-HIF1α-FBLN5 signaling pathway.
- Over-Expression of ARID3B Suppresses Tumor Progression and Predicts Better Prognosis in Patients With Gastric Cancer.
- Gastric cancer derived exosomal THBS1 enhanced Vγ9Vδ2 T-cell function through activating RIG-I-like receptor signaling pathway in a N6-methyladenosine methylation dependent manner.
- Hsa-circ-0052001 promotes gastric cancer cell proliferation and invasion via the MAPK pathway.
- B7-H3 confers stemness characteristics to gastric cancer cells by promoting glutathione metabolism through AKT/pAKT/Nrf2 pathway.
- Identification of gastric signet ring cell carcinoma based on endoscopic images using few-shot learning.
- GADD45B regulates the carcinogenesis process of chronic atrophic gastritis and the metabolic pathways of gastric cancer.
- Clinical significance of CD155 expression and correlation with cellular components of tumor microenvironment in gastric adenocarcinoma.
- Knockdown of LINC01087 inhibits gastric cancer malignant behavior by regulating the miR-135a-5p/CAAP1 axis.
- LncRNA RUNX1-IT1 is downregulated in gastric cancer and suppresses the maturation of miR-20a by binding to its precursor.
- miRNA-223-3p regulates ECT2 to promote proliferation, invasion, and metastasis of gastric cancer through the Wnt/β-catenin signaling pathway.
- B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy.
- Integrated multi-dimensional analysis highlights DHCR7 mutations involving in cholesterol biosynthesis and contributing therapy of gastric cancer.
- MiR-200/183 family-mediated module biomarker for gastric cancer progression: an AI-assisted bioinformatics method with experimental functional survey.
- Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment.
- An evaluation of the use of double-curved endoscopes for gastric gastrointestinal stromal tumors.
- CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1.
- TRIM69 suppressed the anoikis resistance and metastasis of gastric cancer through ubiquitin‒proteasome-mediated degradation of PRKCD.
- Learning curve for endoscopic resection of gastric gastrointestinal stromal tumors: a single-center experience.
- Risk factors for conversion from endoscopic resection to laparoscopic resection for gastric gastrointestinal stromal tumors.
- The added value of radiomics from dual-energy spectral CT derived iodine-based material decomposition images in predicting histological grade of gastric cancer.
- Activation of WNT/CTNNB1/TCF7L2 in Epstein-Barr virus-positive gastric cancer regulates epithelial mesenchymal transition.
- Circular RNA circ_0001017 Sensitizes Cisplatin-Resistant Gastric Cancer Cells to Chemotherapy by the miR-543/PHLPP2 Axis.
- MicroRNA-642b-3p functions as an oncomiR in gastric cancer by down-regulating the CUB and sushi multiple domains protein 1/smad axis.
- Risk Factors and Timing of Additional Surgery after Noncurative ESD for Early Gastric Cancer.
- Evaluation of the role of soluble B7-H3 in association with membrane B7-H3 expression in gastric adenocarcinoma.
- Gastric cancer-derived exosomal miR-135b-5p impairs the function of Vγ9Vδ2 T cells by targeting specificity protein 1.
- Cancer-associated fibroblast-released extracellular vesicles carrying miR-199a-5p induces the progression of gastric cancer through regulation of FKBP5-mediated AKT1/mTORC1 signaling pathway.
- Adenosine triphosphate-based tumor chemosensitivity assay may predict the clinical outcomes of gastric cancer patients receiving taxane-based post-operative adjuvant chemotherapy.
- Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients.
- Steroid Receptor Coactivator-1 (SRC-1) Promoted Cell Metastasis of Gastric Cancer via VEGFC Activator by NF-κB.
- miR-622 Counteracts the NUAK1-Induced Gastric Cancer Cell Proliferation and the Antioxidative Stress.
- Roux-en-Y reconstruction alleviates radical gastrectomy-induced colitis via down-regulation of the butyrate/NLRP3 signaling pathway.
- The Deubiquitinating Enzyme USP4 Functions as an Oncoprotein in Gastric Cancer and Mediates NF-κB Signaling by Regulating PRL-3 Expression.
- A vasculogenic mimicry prognostic signature associated with immune signature in human gastric cancer.
- Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.
- Diagnosis value of miR-181, miR-652, and CA72-4 for gastric cancer.
- Establishment of a Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assay to Measure Soluble B7-H5 in Patients with Cancer.
- Clinical Value of Pepsinogen in the Screening, Prevention, and Diagnosis of Gastric Cancer.
- Billroth II anastomosis maintains SMI and BMI better than Roux-en-Y anastomosis following totally laparoscopic distal gastrectomy: a propensity score-matched study.
- PRKAA1, stabilized by FTO in an m6A-YTHDF2-dependent manner, promotes cell proliferation and glycolysis of gastric cancer by regulating the redox balance.
- LINC00922 acts as a novel oncogene in gastric cancer.
- Evaluating health-related quality of life in gastric cancer patients in Suzhou, China.
- Chinese and global burdens of gastric cancer from 1990 to 2019.
- H19 promotes aerobic glycolysis, proliferation, and immune escape of gastric cancer cells through the microRNA-519d-3p/lactate dehydrogenase A axis.
- Application of Hemocoagulase Bothrops Atrox in the submucosal injection for endoscopic submucosal dissection: a preliminary trial.
- ONECUT2 which is targeted by hsa-miR-15a-5p enhances stemness maintenance of gastric cancer stem cells.
- LncRNA-HEIH is a Novel Diagnostic and Predictive Biomarker in Gastric Cancer.
- LINC02535 promotes cell growth in poorly differentiated gastric cancer.
- Circular RNA circ_HN1 facilitates gastric cancer progression through modulation of the miR-302b-3p/ROCK2 axis.
- Circular RNA hsa_circ_0072309 inhibits the proliferation, invasion and migration of gastric cancer cells via inhibition of PI3K/AKT signaling by activating PPARγ/PTEN signaling.
- SIRT5 regulates autophagy and apoptosis in gastric cancer cells.
中文论文(未计入)5
- [Risk factors for complications of endoscopic full-thickness resection of upper gastrointestinal submucosal tumors].
- [Study of immunophenotypic characteristics, clinicopathological parameters and prognosis in gastric cancer microenvironment].
- [Analysis of efficacy and safety of a new endoscopic anastomosis clip in the treatment of defects after endoscopic full-thickness resection].
- [Gastric adenocarcinoma with enteroblastic differentiation combined with liver metastasis: report of a case].
- [Application of fecal DNA methylation biomarkers detection in gastric cancer screening].
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
- AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging
- Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
- AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
- A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
- Phase IIT Trial of SNA014
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 3 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 1 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 16 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
牵头的论文4
- A microsphere-vesicle hybrid system for tumor treatment through enhancement of innate and adaptive immune responses.
- GD2-mediated impairment of macrophage phagocytosis drives pulmonary metastasis in osteosarcoma.
- Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo.
- Bioinformatics analysis of key pathways and genes in osteosarcoma development.
早期论文(2016–2020 年)13
- TRIM58 Interacts with Pyruvate Kinase M2 to Inhibit Tumorigenicity in Human Osteosarcoma Cells.
- LINC00612 functions as a ceRNA for miR-214-5p to promote the proliferation and invasion of osteosarcoma in vitro and in vivo.
- The Effects of Interleukin-33 (IL-33) on Osteosarcoma Cell Viability, Apoptosis, and Epithelial-Mesenchymal Transition are Mediated Through the PI3K/AKT Pathway.
- Long non-coding RNA Taurine upregulated gene 1 promotes osteosarcoma cell metastasis by mediating HIF-1α via miR-143-5p.
- Feedback modulation of endothelial cells promotes epithelial-mesenchymal transition and metastasis of osteosarcoma cells by Von Willebrand Factor release.
- MicroRNA-221 regulates osteosarcoma cell proliferation, apoptosis, migration, and invasion by targeting CDKN1B/p27.
- NEAT1 induces osteosarcoma development by modulating the miR-339-5p/TGF-β1 pathway.
- Transcription factor CEBPB inhibits the proliferation of osteosarcoma by regulating downstream target gene CLEC5A.
- MiR-183 inhibits osteosarcoma cell growth and invasion by regulating LRP6-Wnt/β-catenin signaling pathway.
- von Willebrand factor rescued by miR-24 inhibition facilitates the proliferation and migration of osteosarcoma cells in vitro.
- DownRegulated SOX4 Expression Suppresses Cell Proliferation, Migration, and Induces Apoptosis in Osteosarcoma In Vitro and In Vivo.
- Mechanisms of oxidative stress, apoptosis, and autophagy involved in graphene oxide nanomaterial anti-osteosarcoma effect.
- The lncRNA HNF1A-AS1 is a negative prognostic factor and promotes tumorigenesis in osteosarcoma.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 6 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
这些数字背后的记录
牵头的论文6
- Comparison analysis of two different types of endoscopic resection procedures in small gastric subepithelial tumours originating frommuscularis propria.
- An evaluation of the use of double-curved endoscopes for gastric gastrointestinal stromal tumors.
- Learning curve for endoscopic resection of gastric gastrointestinal stromal tumors: a single-center experience.
- Risk factors for conversion from endoscopic resection to laparoscopic resection for gastric gastrointestinal stromal tumors.
- The synergistic therapeutic effect of imatinib and protein kinase CK2 Inhibition correlates with PI3K-AKT activation in gastrointestinal stromal tumors.
- Endoscopic submucosal dissection for ultra-low large rectal stromal tumor after preoperative imatinib therapy: A case report and review.
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 3 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 27 篇,占 1.6%。
苏州有 2 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 17
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
- 分期
- 早期I期
- 开始
- 2025-07
- 登记号
- NCT06730256
年龄 18 岁 至 未注明(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2025-07
- 登记号
- NCT07652138
年龄 18 岁 至 70 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
- 分期
- IV期
- 开始
- 2024-06
- 登记号
- NCT06409702
年龄 18 岁 至 未注明(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
- 分期
- 未注明
- 开始
- 2024-09
- 登记号
- NCT06682156
年龄 18 岁 至 未注明(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
- 分期
- I/II期
- 开始
- 2019-07
- 登记号
- NCT04025450
年龄 18 岁 至 80 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
- 分期
- I/II期
- 开始
- 2016-09
- 登记号
- NCT03196414
年龄 18 岁 至 75 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
- 即将招募A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
- 分期
- IV期
- 开始
- 2026-07
- 登记号
- NCT07709884
年龄 18 岁 至 未注明(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2026-04
- 登记号
- NCT07454187
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心杭州、苏州、西安、郑州
- 正在招募A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
- 分期
- I期
- 开始
- 2026-06
- 登记号
- NCT07490613
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心苏州
- 正在招募Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- 分期
- I期
- 开始
- 2026-03
- 登记号
- NCT07529782
年龄 未注明 至 18 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、杭州、济南、苏州
- 正在招募Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- 分期
- III期
- 开始
- 2026-06
- 登记号
- NCT07555938
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南京、天津、广州、昆明、杭州、武汉、济南、温州、苏州、青岛
- 正在招募A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2026-09
- 登记号
- NCT07760454
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、苏州
- 正在招募A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2024-07
- 登记号
- NCT06083207
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、南京、南宁、天津、徐州、武汉、苏州、西安
- 正在招募A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- 分期
- III期
- 开始
- 2024-06
- 登记号
- NCT06508983
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、天津、广州、杭州、武汉、苏州、西安、郑州
- 正在招募A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2023-10
- 登记号
- NCT06049290
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、厦门、太原、宁波、广州、杭州、武汉、沈阳、海口、深圳、温州、苏州、西安、贵阳、郑州、长春、青岛
- 正在招募A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- 分期
- III期
- 开始
- 2022-11
- 登记号
- NCT05623020
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、天津、广州、杭州、武汉、温州、福州、苏州、长春
- 正在招募A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- II期
- 开始
- 2021-02
- 登记号
- NCT04634552
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、苏州、西安
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文27
- Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone.
- Redefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapy.
- A rare case of concurrent JAK2V617F-positive essential thrombocythemia, multiple myeloma, and colorectal adenocarcinoma.
- A 2D-STI echocardiographic diagnostic model established for cardiac amyloidosis complicated with multiple myeloma.
- Effect of oral care models on the prevention of oral mucositis induced by high-doses of melphalan in patients undergoing ASCT.
- Application of individualized low-protein diet nursing for managing multiple myeloma patients with renal impairment.
- Landscapes of immunoglobulin heavy-chain gene repertoire and its cytogenetic abnormalities in Chinese patients with multiple myeloma.
- Effective Treatment with Venetoclax and Hypomethylating Agents for the Coexistence of Multiple Myeloma and Acute Myeloid Leukemia: A Case Report and Literature Review.
- MRI-based bone marrow radiomics for predicting cytogenetic abnormalities in multiple myeloma.
- Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant.
- Quantitative assessment of bone marrow infiltration and characterization of tumor burden using dual-layer spectral CT in patients with multiple myeloma.
- Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
- Autologous stem cell transplantation in multiple myeloma patients with renal impairment.
- Discriminating minimal residual disease status in multiple myeloma based on MRI: utility of radiomics and comparison of machine-learning methods.
- Increased expression of CEP72 predicts poor prognosis in multiple myeloma.
- Nursing care of patients with relapsed and refractory multiple myeloma treated with B-cell mature antigen-targeted universal chimeric antigen receptor T cells.
- Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma.
- Apparent diffusion coefficient measurements of bone marrow infiltration patterns in multiple myeloma for the assessment of tumor burden - a feasibility study.
- Cystatin C and eGFRCKD-EPI-CysC: novel biomarkers for renal impairment diagnosis and two-year progression-free survival in multiple myeloma.
- Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma.
- Successful eradication of central nervous system infiltration of primary plasma cell leukemia by temozolomide.
- Pulsatilla saponin A Induces Apoptosis and Differentiation of Myeloma Cells.
- C3a and C5a facilitates the metastasis of myeloma cells by activating Nrf2.
- Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
- Inhibition of the Otub1/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis.
- Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement.
- Quantitative evaluation of bone marrow infiltration using dual-energy spectral computed tomography in patients with multiple myeloma.
中文论文(未计入)19
- [Renal response and prognosis of newly diagnosed patients with multiple myeloma with renal impairment applying VRD and autologous hematopoietic stem cell transplantation].
- [Effect of Recombinant Human Thrombopoietin on Platelet Reconstitution after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma].
- [Interpretation of minimal residual disease for response evaluation in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].
- [Interpretation of risk stratification in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].
- [Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma].
- [Clinical significance and pathogenesis analysis of Moesin in multiple myeloma].
- [Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma].
- [Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma].
- [The Role of Whole Body DWI in the Evaluation of Bone Disease in Multiple Myeloma].
- [Efficacy of total oral regimens containing ixazomib in patients with relapsed and refractory multiple myeloma].
- [Efficacy and safety of lenalidomide combined with bortezomib and dexamethasone induction therapy in newly diagnosed patients with multiple myeloma].
- [Multiple myeloma with chromothripsis: three cases report].
- [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].
- [The expression level of secretory mature B cell surface antigen in primary diagnosed multiple myeloma and its clinical significance].
- [Preliminary exploration of the metabolic profile and metabolic pathways in newly diagnosed multiple myeloma].
- [Application of Conditioning Regimen with Busulfan and Cyclophosphamide in Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma].
- [The Effects of Chidamide Combined with Anti-myeloma Drugs on the Proliferation and Apoptosis of Myeloma Cells].
- [Clinical Features and Prognostic Factors of Patients with Multiple Myeloma].
- [Characteristics of immunoglobulin heavy-chain gene clonal rearrangements by next-generation sequencing of patients with multiple myeloma].
它在 ClinicalTrials.gov 上的全部试验(任何状态)49
- A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
- Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
- A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
- Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
- Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
- Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
- Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
- An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma
- Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
- CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.
- Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#
- Cohort Construction and Prognostic Model Construction for Multiple Myeloma
- A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma
- Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM
- A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
- Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
- Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients
- PDD vs PAD to Treat Initially Diagnosed MM
- Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
- To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
- Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- A Study of Daratumumab
- A Study of NINLARO® in Chinese Adults With Multiple Myeloma
- APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study of Ninlaro in Real World Clinical Practice in China
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
- Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 12 篇,占 5.3%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 2 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下
这家医院参与的开放试验 10
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
- 分期
- I期
- 开始
- 2026-09
- 登记号
- NCT07854652
年龄 14 岁 至 75 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
- 分期
- II期
- 开始
- 2025-05
- 登记号
- NCT06985485
年龄 15 岁 至 未注明(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
- 分期
- II期
- 开始
- 2025-04
- 登记号
- NCT07564453
年龄 15 岁 至 65 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
- 分期
- II期
- 开始
- 2024-02
- 登记号
- NCT06250959
年龄 15 岁 至 65 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
- 分期
- II期
- 开始
- 2024-04
- 登记号
- NCT06393985
年龄 18 岁 至 65 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
- 分期
- I期
- 开始
- 2024-04
- 登记号
- NCT06507514
年龄 15 岁 至 65 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
- 分期
- 早期I期
- 开始
- 2024-12
- 登记号
- NCT06696833
年龄 14 岁 至 未注明(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募CAV Regimen for R/R Ph- B-ALL
- 分期
- 不分期
- 开始
- 2022-10
- 登记号
- NCT05657652
年龄 15 岁 至 70 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
- 即将招募U96-CAR-T-Cells For R/R B-ALL
- 分期
- I期
- 开始
- 2026-07
- 登记号
- NCT07511426
年龄 18 岁 至 未注明(登记的条件)
牵头:苏州大学附属第一医院苏州
- 即将招募Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
- 分期
- 早期I期
- 开始
- 2024-09
- 登记号
- NCT06559644
年龄 18 岁 至 70 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文12
- Shorter Duration of Blinatumomab Administration to 14 Days Has Same Efficacy and Safety Profile in Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.
- A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphob
- Genetic and clinical characteristics of acute B-cell lymphoblastic leukemia with MEF2D fusions and report of two novel MEF2D rearrangements.
- Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease.
- Reduced-dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B-cell acute lymphoblastic leukemia.
- Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion.
- Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia.
- Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial.
- Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.
- Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
- CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and E
- Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration.
中文论文(未计入)4
- [Clinical analysis of 7 cases of acute B cell lymphoblastic leukemia with t (17;19) (q21-22;p13)/TCF3-HLF fusion].
- [Clinical efficacy and safety of blinatumomab bridging CAR-T cell therapy in the treatment of patients with adult acute B-cell lymphoblastic leukemia].
- [Effect of MXRA7 on the Biological Functions of Acute B Lymphoblastic Leukemia Cell Line REH].
- [Ph-like B-cell acute lymphoblastic leukemia with ZEB2-JAK2 fusion gene positivity: a case report].
它在 ClinicalTrials.gov 上的全部试验(任何状态)23
- U96-CAR-T-Cells For R/R B-ALL
- BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
- Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
- Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
- Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
- Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
- Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
- CAV Regimen for R/R Ph- B-ALL
- Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL
- CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).
- ThisCART19A Bridging to alloHSCT for R/R B-ALL
- Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL
- CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
- Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia(R/R-ALL)
- CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia
- CAR-T Cell Therapy Targeting to CD19 for R/R ALL
- RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
- Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL
- A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
- CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
- Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
- CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
血液疾病
再生障碍性贫血
Aplastic anaemia2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 11 篇,占 2.7%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 3 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
- 分期
- II期
- 开始
- 2026-01
- 登记号
- NCT07400341
年龄 18 岁 至 65 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
- 正在招募A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
- 分期
- 不分期
- 开始
- 2025-10
- 登记号
- NCT07499284
年龄 14 岁 至 未注明(登记的条件)
牵头:苏州大学附属第一医院;另有 2 家列出的医院为研究中心徐州、杭州、苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文11
- Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence.
- First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study.
- The Role of Pre-existing Anti-HLA Antibodies in Severe Aplastic Anemia Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation.
- Severe aplastic anemia patients with infection who received an allogeneic hematopoietic stem cell transplantation had a better chance: Long-term outcomes of a multicenter study.
- Comparison of Haploidentical Hematopoietic Stem Cell Transplant With or Without Unrelated Cord Blood Infusion in Severe Aplastic Anemia: Outcomes of a Multicenter Study.
- Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study.
- Lessons from a patient with severe aplastic anemia complicated with COVID-19.
- Outcomes of severe aplastic anemia patients with infection proceeding with allogeneic hematopoietic stem cell transplantation, versus patients without infection.
- A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia.
- Comparison of 2 Different Rabbit Anti-Thymocyte Globulin (r-ATG) Preparations: Thymocyte r-ATG versus T Lymphoblast Cell Line r-ATG in Allogeneic Hematopoietic Stem Cell Transplantation for Acquired Severe Aplastic Anemia: Propensity Score-
- First-Line Unrelated Double-Unit Umbilical Cord Blood Transplantation for Acquired Severe Aplastic Anemia.
中文论文(未计入)3
- [The effect of cytomegalovirus and EB virus activation on hematopoietic reconstitution after intensive immunosuppressive therapy for severe aplastic anemia].
- [Positive rates and distribution characteristics of pre-existing anti-human-leukocyte-antigen antibodies in patients with different hematological diseases].
- [Sibling hematopoietic stem cell transplantation for treatment of severe aplastic anemia complicated with antiphospholipid syndrome: a case report].
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.5%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 2 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
- 分期
- IV期
- 开始
- 2025-11
- 登记号
- NCT07270835
年龄 14 岁 至 80 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
- 即将招募Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
- 分期
- II/III期
- 开始
- 2025-06
- 登记号
- NCT06951971
年龄 1 岁 至 70 岁(登记的条件)
牵头:苏州大学附属第一医院苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文6
- Low-dose emapalumab combined with chemotherapy for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
- Combined emapalumab and ruxolitinib in patients with haemophagocytic Lymphohistiocytosis.
- Myelodysplastic syndrome associated-haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre.
- Successful Treatment of Refractory EBV-Associated Hemophagocytic Lymphohistiocytosis with Combined Emapalumab and PD-1 Blockade.
- An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis.
- Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
PubMed 以外找到的论文(未计入)5
- Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis
- Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients
- Myelodysplastic Syndrome Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Study of 15 Cases in a Single Center
- The Clinical Significance and Prognostic Value of Serum Beta-2 Microglobulin in Adult Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 326 Patients
- Additional file 2 of NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis
血液疾病
β 地中海贫血
Beta thalassaemia2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 1 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。
血液疾病
血友病 A
Haemophilia A2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 6 篇,占 2.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
苏州有 2 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- 分期
- II/III期
- 开始
- 2024-01
- 登记号
- NCT06111638
年龄 18 岁 至 未注明;仅男性(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心Xi’an、北京、天津、广州、成都、昆明、武汉、苏州、贵阳、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文6
- Macrophage membrane-encapsulated miRNA nanodelivery system for the treatment of hemophilic arthritis.
- Incidence of deep venous thrombosis in patients with hemophilia undergoing bilateral simultaneous total knee arthroplasty: a retrospective cohort study.
- Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.
- Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C.
- The coexistence of antiβ2 glycoprotein 1 antibody antibody has no effect on hemophilia A patient.
- No Benefit to Platelet-rich Plasma Over Placebo Injections in Terms of Pain or Function in Patients with Hemophilic Knee Arthritis: A Randomized Trial.
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
- A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
- A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
- PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
- China ADVATE PTP Study
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 5 篇,占 7.8%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Construction of a Database for TTP
- 分期
- 未注明
- 开始
- 2022-10
- 登记号
- NCT05571774
年龄未注明(登记的条件)
牵头:苏州大学附属第一医院苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Association between N-acetylcysteine treatment and in-hospital mortality in adult patients with acquired thrombotic thrombocytopenic purpura: a cohort study.
- Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
- Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment.
- Prognostic value of dynamic cardiac biomarkers in patients with acquired refractory thrombocytopenic purpura: A retrospective study in Chinese population.
- Clinical characteristics and outcomes of adult patients with acquired thrombotic thrombocytopenic purpura: a single center retrospective study.
中文论文(未计入)5
- [The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP].
- [Relapsed immune thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus: a case report and literature review].
- [A combined regimen based on bortezomib and glucocorticoids for 6 patients with recurrent/refractory immune thrombotic thrombocytopenic purpura].
- [Clinical diagnosis and treatment of hereditary thrombocytopenia and purpura: a report of five cases and literature review].
- [Research Advance in Treatment of Thrombotic Thrombocytopenic Purpura --Review].
早期论文(2016–2020 年)5
- Novel mutations in ADAMTS13 CUB domains cause abnormal pre-mRNA splicing and defective secretion of ADAMTS13.
- [Effect of Recombinant Protein in the Spacer Domain on ADAMTS13 Activity].
- [Research Advances of Acquired Thrombotic Thrombocytopenic Purpura--Review].
- [The diagnostic value of PLASMIC score in the discrimination between thrombotic thrombocytopenic purpura and disseminated intravascular coagulation].
- [Progress of acquired thrombotic thrombocytopenic purpura].
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 10 篇,占 2.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 1 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。
这些数字背后的记录
牵头的论文10
- Exploring the causal role of gut microbiota and inflammatory proteins in neuromyelitis optica spectrum disorder: A Mendelian randomization study with mediation analysis.
- Correlation of GABA+ levels in the medial prefrontal cortex and circulating follicular helper T cells in neuromyelitis optica spectrum disorder patients with cognitive impairment.
- Vitamin D status and neuromyelitis optica spectrum disease: A systematic review and meta-analysis.
- Aberrant hippocampal intrinsic morphological connectivity patterns in Neuromyelitis optica spectrum disorder with cognitive impairment: Insights from an individual-based morphological brain network.
- Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
- B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study.
- Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
- Altered functional connectivity associated with cognitive impairment in neuromyelitis optica spectrum disorder.
- Reduced GABA levels in the medial prefrontal cortex are associated with cognitive impairment in patients with NMOSD.
- Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 9 篇,占 1.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
苏州有 1 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Myasthenia Gravis Registry in China
- 分期
- 未注明
- 开始
- 2024-02
- 登记号
- NCT06241521
年龄未注明(登记的条件)
牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文9
- Relative change rate of anti-acetylcholine receptor antibodies concentration Correlates with the recurrence of myasthenia gravis in AChR-Abs-positive patients.
- Expression of lymphocyte activation gene-3 on CD4+T cells is regulated by cytokine interleukin-18 in myasthenia gravis.
- The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.
- Neurometabolic and Brain Functional Alterations Associated with Cognitive Impairment in Patients with Myasthenia Gravis: A Combined 1H-MRS and fMRI Study.
- Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis.
- Association between myasthenia gravis and cognitive disorders: a PRISMA-compliant meta-analysis.
- Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis.
- Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
- Primary biliary cirrhosis associated with myasthenia gravis after postpartum: a case report.
其他疾病
烟雾病
Moyamoya disease2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
苏州有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- 分期
- 未注明
- 开始
- 2026-08
- 登记号
- NCT07894107
年龄 12 岁 至 70 岁(登记的条件)
牵头:首都医科大学附属北京天坛医院;另有 12 家列出的医院为研究中心上海、北京、南昌、成都、杭州、武汉、苏州、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文3
- SDF-1/CXCR4 axis participants in the pathophysiology of adult patients with moyamoya disease.
- Data-Independent Acquisition-Based Serum Proteomic Profiling of Adult Moyamoya Disease Patients Reveals the Potential Pathogenesis of Vascular Changes.
- Assessment of Transient Cerebral Hemodynamic Disturbance via Whole-Brain Computed Tomography Perfusion After Extracranial-Intracranial Bypass in Ischemic Moyamoya Disease.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
肝豆状核变性
Wilson disease2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 1 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝豆状核变性开放试验。
这些数字背后的记录
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 3 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
牵头的论文3
- Novel functional eQTL-SNPs associated with susceptibility to occupational pulmonary fibrosis: A multi-stage study.
- Urine-Derived Stem Cells Reverse Bleomycin‑Induced Experimental Pulmonary Fibrosis by Inhibition of the TGF-β1-Smad2/3 Pathway.
- IL18R1-Related Molecules as Biomarkers for Asthma Severity and Prognostic Markers for Idiopathic Pulmonary Fibrosis.
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
苏州有 1 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
- 分期
- I/II期
- 开始
- 2026-06
- 登记号
- NCT06726577
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
脊髓性肌萎缩症
Spinal muscular atrophy2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 2 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
法布雷病
Fabry disease2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 3 篇,占 4.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
苏州有 3 家医院列在法布雷病下全国有 85 家医院列在法布雷病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- 分期
- 未注明
- 开始
- 2025-11
- 登记号
- NCT07187440
年龄 7 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 18 家列出的医院为研究中心北京、南京、合肥、哈尔滨、天津、太原、成都、杭州、汕头、深圳、石家庄、福州、苏州、西安
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文3
- Multimodality imaging assessment of cardiac involvement in classic and late-onset Anderson-Fabry disease.
- Characteristics of atrial ventricular coupling and left atrial function impairment in early Fabry disease patients using two-dimensional speckle tracking echocardiography.
- The value of myocardial work in patients with left ventricular hypertrophy.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 2 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
其他疾病
白塞病
Behçet disease2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
苏州有 3 家医院列在白塞病下全国有 149 家医院列在白塞病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- 分期
- III期
- 开始
- 2023-11
- 登记号
- NCT06145893
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 7 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)3
- BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6/NF‑κB signaling pathway in glomerular mesangial cells.
- Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective study.
- CCL20 secreted from IgA1-stimulated human mesangial cells recruits inflammatory Th17 cells in IgA nephropathy.
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 4 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 1 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
联系这家医院
出示给工作人员或司机的院名卡
苏州大学附属第一医院
First Affiliated Hospital of Soochow University
苏州
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。